Jan 2016 The Translational Scientist article: "Untangling Tau As a neurologist, Bradley Hyman has seen first-hand the impact of Alzheimer’s disease on patients and their families. His lab examines the genetic and neuropathophysiological factors that play a part in the disease, and recently discovered a rare pathological form of the tau protein, which may hold the key to how Alzheimer’s spreads through the brain."
Jan 2016 The Translational Scientist article: "Animal Alternatives Could the lab rat be heading for retirement? A new breed of in vitro tissues and organs are being engineered to replace animal models – and the developers aim to make them accessible to all."
Jan 2016 The Translational Scientist article: "The Overactive Brain Michela Gallagher was studying aging in lab rats when an unusual finding launched her on a translational journey that now sees her poised to initiate a Phase III trial of a drug to delay the onset of Alzheimer’s dementia."
MassTERi’s mission is to: foster a culture of entrepreneurship at UMass Medical School and facilitate dynamic partnerships with industry, bridge the gap between UMMS discoveries and their development into drugs, products, technologies and companies, educate and nurture the next generation of translational scientists and entrepreneurs, benefit the public good through development and commercialization of new therapies and creation of high-value life science jobs.
2014 Clinical Translational Scientist Career Achievement recipient Dr. Ralph Clayman. Dean Clayman's focus has been the use of technology to transform surgical procedures to minimally invasive and noninvasive therapies which have proven to be equally effective and a better option for the patient. Dr. Clayman is universally recognized as a world-class physician scientist in urology and beyond. www.icts.uci.edu